indazoles and abt 869
indazoles has been researched along with abt 869 in 54 studies
Research
Studies (54)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (29.63) | 29.6817 |
| 2010's | 37 (68.52) | 24.3611 |
| 2020's | 1 (1.85) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Albert, DH; Bouska, JJ; Bousquet, PF; Bukofzer, GT; Dai, Y; Davidsen, SK; Donawho, CK; Ghoreishi-Haack, NS; Glaser, KB; Guo, J; Hartandi, K; Johnson, EF; Li, J; Luo, Y; Magoc, TJ; Marcotte, PA; McCall, JO; Michaelides, MR; Niquette, AL; Pease, LJ; Reuter, DR; Soni, N; Stavropoulos, JA; Tapang, P; Wang, B; Wang, YC; Wei, RQ | 1 |
| Dai, Y; Davidsen, SK; Glaser, KB; Guo, J; Marcotte, PA; McCall, JO; Michaelides, MR; Pease, LJ | 1 |
| Albert, DH; Fesik, SW; Li, L; Lin, X; Shen, Y; Shoemaker, AR | 1 |
| El-Shourbagy, TA; Ji, QC; Kim, JC; Rodila, RC | 1 |
| El-Shourbagy, TA; Gage, EM; Ji, QC; Rodila, RC; Schmidt, JM; Wang, PG; Zhang, J | 1 |
| Albert, DH; Bouska, JJ; Chang, JC; Dai, Y; Davidsen, SK; Glaser, KB; Guo, J; Hartandi, K; Johnson, EF; Li, J; Marcotte, PA; Michaelides, MR; Moore, TB; Osterling, DJ; Owen McCall, J; Pease, LJ; Priceman, SJ; Rhodes, K; Sakamoto, KM; Shah, N; Shankar, DB; Soni, N; Tapang, P; Wei, RQ | 1 |
| Ahmed, AA; Albert, DH; Bauch, JL; Bouska, JJ; Bousquet, PF; Cunha, GA; Dai, Y; Davidsen, SK; Glaser, KB; Guo, J; Harris, CM; Hartandi, K; Hickman, D; Ji, Z; Li, J; Marcotte, PA; Marsh, KC; Martin, RL; Michaelides, MR; Moskey, MD; Olson, AM; Osterling, DJ; Pease, LJ; Reuter, DR; Soni, NB; Stewart, KD; Stoll, VS; Tapang, P | 1 |
| Albert, DH; Bi, C; Chen, CS; Davidsen, SK; Glaser, KB; Han, JH; Lilly, M; Lim, YP; Loh, SL; Pan, M; Tai, YC; Xie, Z; Zhou, J | 1 |
| Albert, DH; Bi, C; Chen, CS; Davidsen, SK; Glaser, KB; Jasinghe, VJ; Khng, J; Lu, Y; Neo, CH; Pan, M; Poon, LF; Xie, Z; Yeoh, AE; Yu, H; Zhou, J | 1 |
| El-Shourbagy, TA; Norem, K; Wu, H; Zhang, J | 1 |
| Albert, DH; Chen, CS; Davidsen, SK; Glaser, KB; Jasinghe, VJ; Khng, J; Poon, LF; Senthilnathan, P; Xie, Z; Zhou, J | 1 |
| Albert, DH; Bi, C; Chen, CS; Chng, WJ; Davidsen, SK; Glaser, KB; Janakakumara, JV; Liu, SC; Palaniyandi, S; Poon, LF; Tay, KG; Xie, Z; Yu, H; Zhou, J | 1 |
| Albert, DH; Banfor, PN; Cox, BF; Davidsen, SK; Franklin, PA; Fryer, RM; Gintant, GA; Segreti, JA; Widomski, DL | 1 |
| Albert, DH; Banfor, PN; Cox, BF; Davidsen, SK; Franklin, PH; Fryer, RM; Gintant, GA; Larson, KJ; Noonan, WT; Segreti, JA; Tapang, P; Widomski, DL | 1 |
| Albert, DH; Chen, CS; Goh, BC; Zhou, J | 1 |
| Chen, CS; Goh, BC; Gupta, N; Hartono, S; Humerickhouse, R; Koh, TS; Lee, SC; Lim, R; Lim, SE; McKeegan, E; Ong, AB; Pradhan, R; Soo, R; Steinberg, J; Sukri, N; Thng, CH; Wong, CI; Wong, J; Yong, WP | 1 |
| Denny, CT; Federman, N; Glaser, KB; Ikeda, AK; Judelson, DR; Landaw, EM; Sakamoto, KM | 1 |
| Goh, BC; Hartono, S; Humerickhouse, RA; Koh, TS; Low, AS; Ong, AB; Rumpel, H; Soo, RA; Sukri, N; Tai, BC; Thng, CH; Wong, CI | 1 |
| Glaser, KB; Griffith, D; Heinrich, MC; Hernandez-Davies, JE; Landaw, EM; Presnell, A; Sakamoto, KM; Tan, X; Zape, JP | 1 |
| Albert, DH; Davidsen, SK; Fox, GB; Jiang, F; Lesniewski, R; Luo, Y; McKeegan, EM; Tapang, P; Zhang, K | 1 |
| Besse, B; Carlson, DM; Gandara, DR; Goss, GD; Gupta, N; Hanna, NH; Hensing, T; Lee, C; Mazieres, J; Pradhan, R; Qian, J; Qin, Q; Ricker, JL; Salgia, R; Scappaticci, FA; Soo, RA; Tan, EH; Thertulien, R; Wertheim, M; Yang, JC | 1 |
| Chang, YI; Chao, YS; Chen, CP; Chen, CT; Chen, CW; Cheng, AH; Chou, LH; Hsieh, SY; Hsu, JT; Hsu, T; Huang, YL; Jiaang, WT; Lin, WH; Lu, CT; Tseng, YJ; Yeh, TK; Yen, KR; Yen, SC | 1 |
| Appleman, LJ; Carlson, DM; Chen, J; Cho, D; Choueiri, TK; Coates, A; Ernstoff, MS; Gupta, N; Kollmannsberger, CK; Michaelson, MD; Perry, DJ; Posadas, EM; Pradhan, R; Qian, J; Ricker, JL; Scappaticci, FA; Tannir, NM; Wong, YN | 1 |
| Albert, DH; Chakravartty, A; Cole, TB; Cox, BF; Davidsen, SK; Fox, GB; Hradil, VP; Jiang, F; Luo, Y; McKeegan, EM; Reuter, D | 1 |
| Chang, CY; Chang, KY; Chang, TY; Chao, YS; Chen, CP; Chen, CT; Chen, CW; Hsieh, SY; Hsu, JT; Huang, YL; Jiaang, WT; Lin, WH; Yeh, TK; Yen, KJ; Yen, SC | 1 |
| Albert, DH; Carlson, DM; Dudley, M; Enschede, S; Glaser, K; Hogge, D; Koh, LP; Li, X; McKeegan, E; Pradhan, R; Stock, W; Wang, ES; Yee, K | 1 |
| Albert, DH; Day, M; Fox, GB; Hickson, JA; Luo, Y; Mudd, SR; Refici-Buhr, M; Reuter, DR; Tapang, P; Voorbach, MJ | 1 |
| Ansell, PJ; Asahina, H; Carlson, DM; Chiu, YL; Coates, A; Goto, Y; Li, X; McKee, MD; McKeegan, EM; Nokihara, H; Pradhan, R; Seki, Y; Shibata, T; Tamura, T; Tamura, Y; Tanioka, M; Yamada, Y; Yamamoto, N | 1 |
| Ansell, P; Carlson, DM; Carr, BI; Chen, PJ; Dowell, B; Gill, S; Knox, JJ; McKeegan, EM; Pedersen, M; Qian, J; Qin, Q; Ricker, JL; Scappaticci, FA; Toh, HC; Yong, WP | 1 |
| Chen, CS; de Necochea-Campion, R; Ferris, RL; Gridley, DS; Hsu, HW; Hu, S; Kim, PD; Mirshahidi, S | 1 |
| Albert, DH; Fox, GB; Ji, S; Liu, S; Luo, Y; Mudd, SR; Shao, G; Voorbach, MJ; Zhang, Y; Zhou, Y | 1 |
| Carlson, DM; Chiu, YL; Pradhan, RS; Ricker, JL | 1 |
| Awni, W; Carlson, DM; Chiu, YL; Hosmane, B; Lorusso, P; Ricker, JL | 1 |
| Carlson, D; Koenig, D; Salem, AH | 1 |
| Ji, S; Liu, S; Shao, G; Zheng, Y; Zhou, Y | 1 |
| Chen, CS; de Necochea-Campion, R; Duerksen-Hughes, PJ; Ferris, RL; Hsu, HW; Mirshahidi, S; Simental, AA; Williams, V | 1 |
| Carlson, DM; Horai, T; Horiike, A; Horinouchi, H; Kaneda, H; McKee, MD; Nakagawa, K; Nishio, M; Nokihara, H; Ohyanagi, F; Okabe, T; Tamura, T; Terashima, M; Xiong, H; Yamamoto, N | 1 |
| Chiu, YL; LoRusso, P; Ricker, JL; Xiong, H | 1 |
| Berlin, J; Cainap, C; Carlson, DM; Fischer, J; Goldberg, RM; Gorbunova, V; Karapetis, CS; Kim, TW; McKee, MD; O'Neil, BH; Qian, J; Qin, Q; Ricker, JL; Van Cutsem, E | 1 |
| Cai, X; Ge, W; Han, W; Huang, W; Jiang, L; Jing, Z; Pan, H; Shou, J; Sui, X; Wang, Z; Xie, J; You, L | 1 |
| Cainap, C; Carlson, DM; Chen, PJ; Cheng, Y; Chung, IJ; El-Nowiem, S; Eskens, FA; Gorbunova, V; Huang, WT; Kang, YK; Kudo, M; McKee, MD; Pan, H; Qian, J; Qin, S; Ricker, JL; Toh, HC | 1 |
| Axelrod, R; Barrios, CH; Belani, CP; Carlson, DM; Devanarayan, V; Gorbunova, VA; Kolman, P; Makhson, A; McKee, MD; McKeegan, EM; Owonikoko, TK; Pereira, JR; Pittman, KB; Qian, J; Qin, Q; Ramalingam, SS; Ricker, JL; Segalla, JG; Shtivelband, M; Soo, RA; Srkalovic, G | 1 |
| Al-Ameedee, M; Marlow, M; Smith, T; Stocks, MJ; Wheeler, S | 1 |
| Aversa, C; Geuna, E; Leone, F; Martinello, R; Milani, A; Montemurro, F; Serini, G; Valdembri, D; Zucchini, G | 1 |
| Ansell, PJ; Bhathena, A; Carlson, DM; Chakravartty, A; Chan, S; Chandran, RK; Davis, G; Devanarayan, V; Dowell, BL; Gawel, SH; McKee, MD; McKeegan, EM; Ramalingam, SS; Ricker, JL | 1 |
| Chen, J; Chen, Z; Guo, J; Liu, M; Pang, X; Wang, J | 1 |
| Ancell, K; Berlin, JD; Cardin, DB; Chan, E; Goff, LW; Smith, SJ; Whisenant, JG; Ye, F | 1 |
| Al-Dafiri, WN; Ibrahim, SA; Khalil, NN; Maher, HM; Zawaneh, AH | 1 |
| Bakheit, AH; Darwish, IA; Hamidaddin, MA; Wani, TA; Zargar, S | 1 |
| Bauer-Brandl, A; Brandl, M; Rosenberg, J; Sironi, D | 1 |
| Berindan-Neagoe, I; Calin, GA; Chen, L; Dan Dumitru, C; Fu, X; Fuentes-Mattei, E; Huang, B; Irimie, A; Ivan, C; Jung, EJ; Lehrer, M; Ling, H; Mafra, ACP; Monroig-Bosque, MDM; Monroig-Bosque, PDC; Nagvekar, R; Nikonowicz, EP; Nouraee, N; Pileczki, V; Redis, RS; Rivera, C; Shah, MY; Zhang, S; Zhang, X | 1 |
| Chu, Y; Hui, X; Jia, S; Jiang, Z; Li, K; Li, P; Loomes, K; Mao, L; Nie, T; Sun, W; Tang, S; Wang, C; Wang, Z; Wu, D; Xu, A; Zhang, Y; Zhao, S; Zhou, Y | 1 |
| Abdel-Rahman, HM; Alsaif, NA; Darwish, IA; Herqash, RN; Khalil, NY; Sayed, AYA | 1 |
Reviews
3 review(s) available for indazoles and abt 869
| Article | Year |
|---|---|
ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Indazoles; Leukemia; Models, Biological; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases | 2009 |
Linifanib.
Topics: Animals; Antineoplastic Agents; Drug Design; Humans; Indazoles; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor | 2010 |
Linifanib: current status and future potential in cancer therapy.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Indazoles; Neoplasms; Neovascularization, Pathologic; Phenylurea Compounds; Protein Kinase Inhibitors | 2015 |
Trials
15 trial(s) available for indazoles and abt 869
| Article | Year |
|---|---|
Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Biomarkers, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Hypertension; Indazoles; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Phenylurea Compounds; Receptor Protein-Tyrosine Kinases; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
A comparative study of dynamic contrast-enhanced MRI parameters as biomarkers for anti-angiogenic drug therapy.
Topics: Adult; Aged; Angiogenesis Inhibitors; Area Under Curve; Biomarkers, Tumor; Demography; Disease Progression; Female; Humans; Indazoles; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neovascularization, Pathologic; Phenylurea Compounds; Statistics, Nonparametric; Time Factors | 2011 |
Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Administration, Oral; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Indazoles; International Agencies; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Phenylurea Compounds; Receptor Protein-Tyrosine Kinases; Salvage Therapy; Survival Rate; Treatment Outcome | 2011 |
Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Phenylurea Compounds; Pyrroles; Sunitinib; Treatment Failure | 2011 |
Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; fms-Like Tyrosine Kinase 3; Humans; Indazoles; Leukemia, Myeloid, Acute; Male; Middle Aged; Phenylurea Compounds; Recurrence; Treatment Outcome | 2012 |
An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Tolerance; Female; Humans; Indazoles; Male; Membrane Proteins; Middle Aged; Neoplasms; Phenylurea Compounds; Receptor Protein-Tyrosine Kinases | 2012 |
Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Diarrhea; Disease-Free Survival; Fatigue; Female; Humans; Indazoles; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Phenylurea Compounds; Treatment Outcome; Tumor Burden; Young Adult | 2013 |
Exposure-response (safety) analysis to identify linifanib dose for a Phase III study in patients with hepatocellular carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Pharmaceutical Solutions; Phenylurea Compounds; Tablets; Young Adult | 2013 |
Results of a phase I, open-label, randomized, crossover study evaluating the effects of linifanib on QTc intervals in patients with solid tumors.
Topics: Cross-Over Studies; Electrocardiography; Humans; Indazoles; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases | 2014 |
A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Non-Small-Cell Lung; Chemotherapy-Induced Febrile Neutropenia; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Japan; Leukopenia; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Severity of Illness Index; Thrombocytopenia; Tumor Burden | 2014 |
Results of a phase 1, randomized study evaluating the effects of food and diurnal variation on the pharmacokinetics of linifanib.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biological Availability; Circadian Rhythm; Cross-Over Studies; Drug Administration Schedule; Fatigue; Female; Food-Drug Interactions; Half-Life; Hand-Foot Syndrome; Humans; Hypertension; Indazoles; Male; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Severity of Illness Index | 2014 |
Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Hypothyroidism; Indazoles; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Phenylurea Compounds; Survival Rate; Thrombocytopenia; Young Adult | 2014 |
Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Administration Schedule; Female; Hand-Foot Syndrome; Humans; Hypertension; Indazoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Odds Ratio; Phenylurea Compounds; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Risk Factors; Sorafenib; Treatment Outcome | 2015 |
Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Indazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Phenylurea Compounds; Receptors, Platelet-Derived Growth Factor; Treatment Outcome; Vascular Endothelial Growth Factor A | 2015 |
Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRAS.
Topics: Adult; Aged; Angiogenesis Inhibitors; Colorectal Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Other Studies
36 other study(ies) available for indazoles and abt 869
| Article | Year |
|---|---|
Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor.
Topics: 3T3 Cells; Animals; Cell Cycle; Cell Division; Cornea; Edema; Enzyme Inhibitors; Female; Indazoles; Mice; Neovascularization, Physiologic; Phenylurea Compounds; Phosphorylation; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Retinal Vessels; Uterus | 2006 |
Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors.
Topics: 3T3 Cells; Adenosine Triphosphate; Animals; Antineoplastic Agents; Benzamides; Binding Sites; Enzyme Inhibitors; Humans; Imatinib Mesylate; Indazoles; Kinetics; Lead; Mice; Phenylurea Compounds; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Macrophage Colony-Stimulating Factor; Signal Transduction; Transfection | 2006 |
Hypoxia-inducible factor-1 inhibition in combination with temozolomide treatment exhibits robust antitumor efficacy in vivo.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Aryl Hydrocarbon Receptor Nuclear Translocator; Caspases; Cell Death; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disease Models, Animal; Dose-Response Relationship, Drug; Glucose; Humans; Hypoxia; Indazoles; Mice; Mice, SCID; Phenylurea Compounds; Structure-Activity Relationship; Temozolomide; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2006 |
A high-throughput, fully automated liquid/liquid extraction liquid chromatography/mass spectrometry method for the quantitation of a new investigational drug ABT-869 and its metabolite A-849529 in human plasma samples.
Topics: Blood Chemical Analysis; Chromatography, High Pressure Liquid; Drug Evaluation, Preclinical; Humans; Indazoles; Microfluidics; Phenylurea Compounds; Reproducibility of Results; Robotics; Sensitivity and Specificity; Solid Phase Microextraction; Spectrometry, Mass, Electrospray Ionization | 2006 |
A high-throughput liquid chromatography/tandem mass spectrometry method for simultaneous quantification of a hydrophobic drug candidate and its hydrophilic metabolite in human urine with a fully automated liquid/liquid extraction.
Topics: Chromatography, High Pressure Liquid; Drugs, Investigational; Humans; Hydrophobic and Hydrophilic Interactions; Indazoles; Phenylurea Compounds; Receptor Protein-Tyrosine Kinases; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2006 |
ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia.
Topics: Animals; Apoptosis; Cell Proliferation; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; fms-Like Tyrosine Kinase 3; G1 Phase; Hematopoietic Stem Cells; Humans; Indazoles; K562 Cells; Ki-67 Antigen; Leukemia, Myeloid, Acute; Mice; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-pim-1; Resting Phase, Cell Cycle; STAT5 Transcription Factor; Tumor Stem Cell Assay; U937 Cells | 2007 |
Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor.
Topics: Adenosine Triphosphate; Administration, Oral; Angiogenesis Inhibitors; Animals; Binding Sites; Edema; Estradiol; Female; Humans; Hydrophobic and Hydrophilic Interactions; Indazoles; Male; Mice; Models, Molecular; NIH 3T3 Cells; Phenylurea Compounds; Phosphorylation; Receptor Protein-Tyrosine Kinases; Structure-Activity Relationship; Uterus; Xenograft Model Antitumor Assays | 2007 |
Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway.
Topics: Acute Disease; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Proteins; Cytarabine; Down-Regulation; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Gene Expression Profiling; Humans; Indazoles; Leukemia, Myeloid; Mice; Mice, SCID; Mitogen-Activated Protein Kinases; Phenylurea Compounds; Proto-Oncogene Proteins c-mos; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Signal Transduction; Transplantation, Heterologous | 2008 |
In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor.
Topics: Antineoplastic Agents; Bone Marrow Transplantation; fms-Like Tyrosine Kinase 3; HL-60 Cells; Humans; Indazoles; Leukemia, Myeloid, Acute; Phenylurea Compounds; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Transplantation, Heterologous | 2008 |
Simultaneous determination of a hydrophobic drug candidate and its metabolite in human plasma with salting-out assisted liquid/liquid extraction using a mass spectrometry friendly salt.
Topics: Acetates; Acetonitriles; Calibration; Chromatography, Liquid; Drugs, Investigational; Humans; Hydrophobic and Hydrophilic Interactions; Indazoles; Mass Spectrometry; Phenylurea Compounds; Quality Control; Reference Standards; Sensitivity and Specificity | 2008 |
ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Movement; Cell Survival; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Indazoles; Liver Neoplasms; Mice; Mice, SCID; Neovascularization, Pathologic; Phenylurea Compounds; Platelet-Derived Growth Factor; Protein Kinases; Receptor Protein-Tyrosine Kinases; Sirolimus; Subcutaneous Fat; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2008 |
Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML.
Topics: Animals; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Epoxy Compounds; Female; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Inhibitor of Apoptosis Proteins; Leukemia, Myeloid, Acute; Ligands; Mice; Mice, Inbred BALB C; Mice, Nude; Microtubule-Associated Proteins; Phenylurea Compounds; Sesquiterpenes; Signal Transduction; STAT3 Transcription Factor; Substrate Specificity; Survivin; Up-Regulation; Xenograft Model Antitumor Assays | 2009 |
ETA receptor blockade with atrasentan prevents hypertension with the multitargeted tyrosine kinase inhibitor ABT-869 in telemetry-instrumented rats.
Topics: Angiogenesis Inhibitors; Animals; Area Under Curve; Atrasentan; Blood Pressure; Dose-Response Relationship, Drug; Drug Interactions; Endothelin A Receptor Antagonists; Heart Rate; Hypertension; Indazoles; Male; Phenylurea Compounds; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Telemetry | 2009 |
Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growt
Topics: Acrylates; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Calcium Channel Blockers; Dose-Response Relationship, Drug; Enalapril; Humans; Imidazoles; Indazoles; Lisinopril; Male; Mice; Mice, SCID; Neoplasms; Nifedipine; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Ramipril; Rats; Rats, Sprague-Dawley; Telmisartan; Thiophenes; Xenograft Model Antitumor Assays | 2009 |
ABT-869 inhibits the proliferation of Ewing Sarcoma cells and suppresses platelet-derived growth factor receptor beta and c-KIT signaling pathways.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Proliferation; Down-Regulation; Humans; Indazoles; Mice; Mice, Inbred NOD; Mice, SCID; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor beta; Sarcoma, Ewing; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
The multitargeted receptor tyrosine kinase inhibitor linifanib (ABT-869) induces apoptosis through an Akt and glycogen synthase kinase 3β-dependent pathway.
Topics: Apoptosis; Cell Line; Cell Proliferation; fms-Like Tyrosine Kinase 3; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Indazoles; Interleukin-3; Lithium Chloride; Mutation; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction | 2011 |
ABT-869, a multitargeted receptor tyrosine kinase inhibitor, reduces tumor microvascularity and improves vascular wall integrity in preclinical tumor models.
Topics: Animals; Capillary Permeability; Cell Line, Tumor; Drug Evaluation, Preclinical; Endothelium, Vascular; Humans; Indazoles; Mice; Neovascularization, Pathologic; Phenylurea Compounds; Receptor Protein-Tyrosine Kinases; Xenograft Model Antitumor Assays | 2011 |
Discovery and evaluation of 3-phenyl-1H-5-pyrazolylamine-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Indazoles; Mice; Molecular Structure; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Sorafenib; Stereoisomerism; Structure-Activity Relationship; Sulfonamides | 2011 |
A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model.
Topics: Animals; Brain Neoplasms; Cell Growth Processes; Disease Models, Animal; Female; Glioma; Immunohistochemistry; Indazoles; Magnetic Resonance Angiography; Neovascularization, Pathologic; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Inbred F344; Receptor Protein-Tyrosine Kinases; Xenograft Model Antitumor Assays | 2012 |
BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML.
Topics: Animals; Benzamides; Cell Proliferation; fms-Like Tyrosine Kinase 3; HEK293 Cells; Humans; Indazoles; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Male; Mice; Mice, Nude; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Sulfonamides; Tumor Cells, Cultured | 2012 |
FDG-PET as a pharmacodynamic biomarker for early assessment of treatment response to linifanib (ABT-869) in a non-small cell lung cancer xenograft model.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Fluorodeoxyglucose F18; Humans; Indazoles; Lung Neoplasms; Mice; Mice, SCID; Phenylurea Compounds; Positron-Emission Tomography; Receptor Protein-Tyrosine Kinases; Xenograft Model Antitumor Assays | 2012 |
Linifanib (ABT-869) enhances radiosensitivity of head and neck squamous cell carcinoma cells.
Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Head and Neck Neoplasms; Humans; Indazoles; Phenylurea Compounds; Radiation Tolerance; Radiation-Sensitizing Agents; Signal Transduction; STAT3 Transcription Factor | 2013 |
Monitoring tumor response to linifanib therapy with SPECT/CT using the integrin αvβ3-targeted radiotracer 99mTc-3P-RGD2.
Topics: Angiogenesis Inhibitors; Animals; Biomarkers, Tumor; Dimerization; Female; Glioma; Humans; Indazoles; Integrin alphaVbeta3; Male; Mice; Mice, Nude; Multimodal Imaging; Oligopeptides; Organotechnetium Compounds; Peptides, Cyclic; Phenylurea Compounds; Positron-Emission Tomography; Prostatic Neoplasms; Protein-Tyrosine Kinases; Radiopharmaceuticals; Technetium; Tomography, X-Ray Computed; Xenograft Model Antitumor Assays | 2013 |
Pooled population pharmacokinetic analysis of phase I, II and III studies of linifanib in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biological Availability; Chemistry, Pharmaceutical; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Male; Meta-Analysis as Topic; Middle Aged; Models, Statistical; Neoplasms; Phenylurea Compounds; Population; Receptor Protein-Tyrosine Kinases; Sex Characteristics; Young Adult | 2014 |
Integrin α(v)β₃-targeted radiotracer (99m)Tc-3P-RGD₂ useful for noninvasive monitoring of breast tumor response to antiangiogenic linifanib therapy but not anti-integrin α(v)β₃ RGD₂ therapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Disease Models, Animal; Drug Monitoring; Indazoles; Integrin alphaVbeta3; Mice; Phenylurea Compounds; Radioactive Tracers; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2013 |
Linifanib (ABT-869), enhances cytotoxicity with poly (ADP-ribose) polymerase inhibitor, veliparib (ABT-888), in head and neck carcinoma cells.
Topics: Apoptosis; Benzimidazoles; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; DNA Breaks; Head and Neck Neoplasms; Histones; Humans; Indazoles; Phenylurea Compounds; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Rad51 Recombinase | 2014 |
Autophagy inhibition sensitizes hepatocellular carcinoma to the multikinase inhibitor linifanib.
Topics: Animals; Autophagy; Carcinoma, Hepatocellular; Cell Survival; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Indazoles; Liver Neoplasms; Mice; Phenylurea Compounds; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
Linifanib--a multi-targeted receptor tyrosine kinase inhibitor and a low molecular weight gelator.
Topics: Hydrogels; Indazoles; Mechanical Phenomena; Molecular Weight; Phenylurea Compounds; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Solvents; Urea | 2015 |
Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanib.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Indazoles; Keratin-19; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Phenylurea Compounds | 2015 |
Linifanib (ABT-869) Potentiates the Efficacy of Chemotherapeutic Agents through the Suppression of Receptor Tyrosine Kinase-Mediated AKT/mTOR Signaling Pathways in Gastric Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Down-Regulation; Drug Synergism; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Mice; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Receptor Protein-Tyrosine Kinases; Signal Transduction; Stomach Neoplasms; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2016 |
Micelle-enhanced direct spectrofluorimetric method for the determination of linifanib: Application to stability studies.
Topics: Calibration; Drug Stability; Fluorescence; Hydrogen-Ion Concentration; Indazoles; Limit of Detection; Micelles; Phenylurea Compounds; Photolysis; Polysorbates; Reproducibility of Results; Solvents; Spectrometry, Fluorescence; Surface-Active Agents; Tablets | 2017 |
Spectrophotometric and molecular modelling studies on in vitro interaction of tyrosine kinase inhibitor linifanib with bovine serum albumin.
Topics: Animals; Binding Sites; Cattle; Indazoles; Molecular Docking Simulation; Phenylurea Compounds; Protein Binding; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Serum Albumin, Bovine; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Thermodynamics | 2017 |
PermeaLoop™, a novel in vitro tool for small-scale drug-dissolution/permeation studies.
Topics: Absorption, Physiological; Chemistry, Pharmaceutical; Drug Liberation; Indazoles; Permeability; Phenylurea Compounds; Tablets | 2018 |
OncomiR-10b hijacks the small molecule inhibitor linifanib in human cancers.
Topics: Breast Neoplasms; Drug Resistance, Neoplasm; Female; Hep G2 Cells; Humans; Indazoles; Liver Neoplasms; Male; MCF-7 Cells; MicroRNAs; Neoplasm Metastasis; Phenylurea Compounds; RNA, Neoplasm | 2018 |
Linifanib exerts dual anti-obesity effect by regulating adipocyte browning and formation.
Topics: 3T3-L1 Cells; Adipocytes, Brown; Adipogenesis; Animals; Anti-Obesity Agents; Cells, Cultured; Dose-Response Relationship, Drug; Indazoles; Mice; Mice, Transgenic; Phenylurea Compounds; Random Allocation; Smegmamorpha; STAT3 Transcription Factor | 2019 |
Charge-Transfer Complex of Linifanib with 2,3-dichloro-3,5-dicyano-1,4-benzoquinone: Synthesis, Spectroscopic Characterization, Computational Molecular Modelling and Application in the Development of Novel 96-microwell Spectrophotometric Assay.
Topics: Indazoles; Models, Molecular; Molecular Structure; Phenylurea Compounds; Proton Magnetic Resonance Spectroscopy; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared | 2021 |